HELP Cybin D/B/A Helus Pharma

Cybin has delivered a 114.8% gain over the past year, which puts a spotlight on whether that kind of share price reset still lines up with what its balance sheet and book value suggest the stock is worth today. With the psychedelic mental health developer now more visible after fresh clinical headlines, the key issue is how much of that story is already embedded in the price investors are paying for its equity cushion. The 114.8% return over the past 12 months raises a straightforward...

Cybin (NasdaqGM:HELP), which is rebranding as Helus Pharma, has just wrapped up a pivotal shareholder meeting approving a legal name change and confirming its full director slate for the coming year. For investors tracking Cybin, the legal rebrand to Helus Pharma comes after a sharp run in the share price over recent months. The 90 day share price return is 116.28% and the 1 year total shareholder return is 115.56%. In contrast, the 3 year total shareholder return is down 37.40% and the 5...

Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead

Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv

Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global Investment Conference. The company, referred to in the presentation as Helus Pharma, is developing se

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline. Speaki

Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major depressive disorder, and the appointment of Michael Halstead as CEO. Cybin’s share price has moved sharply in recent months, with a 1 month share price return of 83.53% and a 90 day share price return of 215.69%. The 1 year total shareholder return of 87.72% contrasts with a weaker 5 year total...

Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along with updates around peers’ late stage programs and regulatory tone, is helping shape how analysts frame this higher fair value range for Cybin. Read on to see how these shifting assumptions and new data points can help you track the evolving narrative around the stock. Stay updated as the Fair...

Psychedelics stocks are becoming more popular as more research goes into them. Here are 3 stock ideas for your watchlist.

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treatment for major depressive disorder. Speaking at a Canaccord Genuity event, Halstead, w

Cybin (HELP) is in focus after Helus Pharma appointed Michael Halstead as Chief Executive Officer on 3 August 2026. He brings 25 years of pharmaceutical leadership across product launches, capital markets and major corporate transactions. See our latest analysis for Cybin. The CEO appointment has come alongside sharp share price momentum for Cybin, with a 7 day share price return of 48.47% and a 90 day share price return of 118.64%, although the 5 year total shareholder return is down...

In August 2026, Helus Pharma appointed Michael Halstead as Chief Executive Officer, bringing 25 years of biopharma experience including leadership roles in major acquisitions and the commercialization of CAPLYTA® across several psychiatric indications. Halstead’s history of helping transform clinical-stage companies into fully integrated commercial organizations, while overseeing large equity offerings and multi‑billion‑dollar sales, is a meaningful reference point for Cybin’s own late‑stage...

Cybin’s updated analyst model features a reduced fair value estimate, with the price target moving from US$49.46 to US$37.57, a cut of about 24% in the projected equity value per share. This change sits against a backdrop of mixed sector commentary on psychedelic drug developers, where optimism around potential pharma deals and regulatory clarity is balanced by caution on valuation resets and deal outcomes. As you read on, you will see how these shifting assumptions feed into the evolving...

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]

Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently completed an underwritten public offering raising about US$50,000,000 to fund development. This combination of late-stage clinical progress and fresh capital support highlights how Cybin is positioning HLP003 as a potential clinic-based mental health therapy within its broader psychedelic treatment...

Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could see a positive read-through after Johnson & Johnson (NYSE:JNJ) reported stronger second-quarter sales for its Spravato depression...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Cybin D/B/A Helus Pharma (NASDAQ:HELP) is one of the best psychedelic stocks on our list. TheFly reported on July 1 that Canaccord analyst Sumant Kulkarni lowered the price target on HELP to $42 from $45 while maintaining a Buy rating […]

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc....